Stage Funding EPICS Therapeutics is in the Series A funding stage with recent €12M and $13.1M financing to advance its oncology pipeline, indicating a growing need for strategic collaborations, co-development deals, and potential licensing opportunities to accelerate program progression.

RNA Epigenetics Focus The company concentrates on RNA epigenetic mechanisms in cancer, presenting a niche for partnerships with people or firms seeking RNA-targeted small molecules, specialized assay development, and translational biomarker opportunities to de-risk and validate programs.

Small Team Scale With 11-50 employees, EPICS is a lean operation likely seeking external expertise for late-stage development, manufacturing, and clinical trial support; this signals opportunities for CRO/CMO partnerships, consulting, and advisory services to scale efficiently.

Leadership Turnover Recent CEO appointment changes (Graeme Fraser in 2024; prior CEO in 2022) suggest a transition phase and potential appetite for strategic partnerships or investment to solidify governance, with outreach aligned to senior leadership for collaborations.

Strategic Partnerships Historical collaboration with Ogeda and a focus on high value-added endpoints point to openness to partnering models; target biotech and pharma players seeking oncology assets, co-development, or asset acquisition in RNA epigenetics cancer space.